COMMENTARY: Atorvastatin did not prevent cardiovascular events in type 2 diabetes

Montori, Victor M.
November 2006
ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p62
Academic Journal
The article presents the author's comments on the efficacy of atorvastatin in preventing cardiocvascular events in type 2 diabetes. A meta-analysis of randomized trials of statins in patients with diabetes that showed a 20% relative risk reduction in major coronary events in the primary prevention groups and 21% in the secondary prevention groups offers the best estimate of statin effects.


Related Articles

  • Diabetes risk of statins increased, but absolute risk low, outweighed by CV benefit. Kalvaitis, Katie // Endocrine Today;Mar2010, Vol. 8 Issue 3, p19 

    The article reports on the finding that the risk of developing type 2 diabetes is increased by nine percent through the use of statins, but there is a low absolute risk when the beneficial effect of statins on the reduction of coronary events is compared.

  • Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Rotella, Carlo M.; Zaninelli, Augusto; Le Grazie, Cristina; Hanson, Mary E.; Gensini, Gian Franco // Lipids in Health & Disease;2010, Vol. 9, p80 

    Background: Treatment guidelines recommend LDL-C as the primary target of therapy in patients with hypercholesterolemia. Moreover, combination therapies with lipid-lowering drugs that have different mechanisms of action are recommended when it is not possible to attain LDL-C targets with statin...

  • Evaluation and Management of Peripheral Neuropathy in Diabetic Patients With Cancer. Visovsky, Constance; Meyer, Rachel R.; Roller, Jeffre; Poppas, Megan // Clinical Journal of Oncology Nursing;Apr2008, Vol. 12 Issue 2, p243 

    Recently, chemotherapy-induced peripheral neuropathy has received a great deal of attention. However, the interaction of diabetic neuropathy with potentially neurotoxic chemotherapy is far less understood. The incidence of type II diabetes has risen exponentially in the past two decades. In...

  • GP Registrar: MRCCP Exam Update - Diabetes and cholesterol. Newson, Louise // GP: General Practitioner;6/10/2005, p81 

    The article reports that patients with type-2 diabetes should be considered as chronic diseases (CHD) risk equivalents and dyslipidaemia should be a key therapeutic target, irrespective of baseline LDL cholesterol levels or age. Many studies have established statins as effective agents in the...

  • Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis. de Vries, Folgerdiena M.; Kolthof, Johan; Postma, Maarten J.; Denig, Petra; Hak, Eelko // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Aims: To estimate the efficacy of standard and intensive statin treatment in the secondary prevention of major cardiovascular and cerebrovascular events in diabetes patients. Methods: A systematic search was conducted in Medline over the years 1990 to September 2013. Randomized, double-blind,...

  • Longer antiplatelet therapy gives good DES outcomes in diabetes mellitus. Lindsay, Alistair C.; Qureshi, Katie // Heart;Jan2009, Vol. 95 Issue 1, p94 

    The article reports on the study about diabetic patients treated with drug-eluting coronary stents (DES) who received short-term, less than six months dual antiplatelet therapy. It is stated that longer antiplatelet therapy gives good DES outcomes in diabetes mellitus. According to the study...

  • The silent killer. Schrof, Joannie M. // U.S. News & World Report;04/12/99, Vol. 126 Issue 14, p50 

    Discusses the prevalence of diabetes in the United States. Concerns about the diabetes drug Rezulin; Expected number of diabetics; Progress in diabetes research; Symptoms and complications; Role of blood sugar; Those who are vulnerable to the disease; Impact of lifestyle on diabetes...

  • Diabetes dilemmas. Gadsby, Roger // Pulse;6/2/2010, Vol. 70 Issue 19, p18 

    The article presents questions and answers related to comorbidity and diabetes complications including the significance of aspirin in the primary prevention of cardiovascular disease, on the impact of statin on diabetic patients, and the low risk of mortality in patients with HbA1c.

  • Adherence to Statin Therapy and LDL Cholesterol Goal Attainment by Patients With Diabetes and Dyslipidemia. Parris, Elizabeth S.; Lawrence, David B.; Mohn, Lisa A.; Long, Laura B. // Diabetes Care;Mar2005, Vol. 28 Issue 3, p595 

    OBJECTIVE -- The purpose of this study was to assess the relationship between adherence to statin therapy and LDL cholesterol goal achievement in patients with diabetes and dyslipidemia. RESEARCH DESIGN AND METHODS -- The records of patients being medically treated for dyslipidemia in a managed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics